![]() Terazosin hydrochloride structure
|
Common Name | Terazosin hydrochloride | ||
---|---|---|---|---|
CAS Number | 63074-08-8 | Molecular Weight | 423.89 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 664.5±65.0 °C at 760 mmHg | |
Molecular Formula | C19H26ClN5O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 355.7±34.3 °C |
Use of Terazosin hydrochlorideTerazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3]. |
Name | Terazosin hydrochloride |
---|---|
Synonym | More Synonyms |
Description | Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3]. |
---|---|
Related Catalog | |
Target |
α1-adrenoceptor[1] |
In Vitro | Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells[1]. |
In Vivo | Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm[3]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 664.5±65.0 °C at 760 mmHg |
Molecular Formula | C19H26ClN5O4 |
Molecular Weight | 423.89 |
Flash Point | 355.7±34.3 °C |
PSA | 103.04000 |
LogP | -0.96 |
Appearance of Characters | powder,white to off-white |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.636 |
Storage condition | Store at RT |
Water Solubility | H2O: 25 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xn,Xi |
---|---|
Risk Phrases | 22-36/37/38 |
Safety Phrases | 26-36 |
WGK Germany | 3 |
RTECS | TK8044925 |
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- |
Terazosin |
UNII:8L5014XET7 |
Vicard |
Itrin |
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone,hydrochloride |
Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)- |
Urodie |
[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)methanone |
6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine |
MFCD00467965 |
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone |